LabCorp Earns 100 Percent on Human Rights Campaign Foundation’s 16th Annual Scorecard on LGBTQ Workplace Equality
Receives Designation as a Best Place to Work for LGBTQ Equality
BURLINGTON, N.C.–(BUSINESS WIRE)–LabCorp (NYSE: LH), a leading global life sciences company, announced
that it received a perfect score of 100 percent on the 2018 Corporate
Equality Index (CEI), a national benchmarking survey and report on
corporate policies and practices related to lesbian, gay, bisexual,
transgender and queer (LGBTQ) workplace equality, administered by the
Human Rights Campaign Foundation.
“We are pleased to receive this recognition,” said David P. King,
chairman and CEO of LabCorp. “At LabCorp, we seek to set an unequivocal
tone and standard of treating every person with dignity and respect. The
CEI recognition demonstrates that our 57,000 colleagues around the globe
hold each other accountable to these values and to a positive work
environment and culture.”
The 2018 CEI rated 947 businesses in the report, which evaluates
LGBTQ-related policies and practices including non-discrimination
workplace protections, domestic partner benefits, transgender-inclusive
health care benefits, competency programs, and public engagement with
the LGBTQ community. LabCorp’s efforts in satisfying all of the CEI’s
criteria resulted in a 100 percent ranking and the designation as a Best
Place to Work for LGBTQ Equality.
This is the first time LabCorp formally participated in the survey,
achieving the highest score on its initial submission.
About the Human Rights Campaign Foundation
The Human Rights Campaign Foundation is the educational arm of America’s
largest civil rights organization working to achieve equality for
lesbian, gay, bisexual, transgender and queer people. For more
information on the 2018 Corporate Equality Index, or to download a free
copy of the report, visit www.hrc.org/cei.
About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global life
sciences company that is deeply integrated in guiding patient care,
providing comprehensive clinical laboratory and end-to-end drug
development services. With a mission to improve health and improve
lives, LabCorp delivers world-class diagnostic solutions, brings
innovative medicines to patients faster and uses technology to improve
the delivery of care. LabCorp reported net revenues of nearly $9.5
billion for 2016. To learn more about LabCorp, visit www.labcorp.com,
and to learn more about Covance Drug Development, visit www.covance.com.
Forward-Looking Statements
This press release contains forward-looking statements including with
respect to estimated 2017 guidance and the impact of various factors on
operating and financial results. Each of the forward-looking statements
is subject to change based on various important factors, including
without limitation, competitive actions in the marketplace, and adverse
actions of governmental and other third-party payers. Actual results
could differ materially from those suggested by these forward-looking
statements. The Company has no obligation to provide any updates to
these forward-looking statements even if its expectations change.
Further information on potential factors that could affect operating and
financial results is included in the Company’s Form 10-K for the year
ended December 31, 2016, and subsequent Forms 10-Q, including in each
case under the heading risk factors, and in the Company’s other filings
with the SEC. The information in this press release should be read in
conjunction with a review of the Company’s filings with the SEC
including the information in the Company’s Form 10-K for the year ended
December 31, 2016, and subsequent Forms 10-Q, under the heading
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
Contacts
LabCorp
Media:
Pattie Kushner, 336-436-8263
or
Investor:
Scott
Frommer, 336-436-5076
